BNET Industries
Market Cap:$10.5M
Last Fiscal Year Sales:$6.0M
- Public
- US
Dow Jones Description
Not stressing over their therapies. Founded in 1965 and headquartered in Portland, OR, OXIS International, Inc. (NASDAQ: OXIS) is a provider of diagnosis and treatment services for oxidative stress-related diseases. Diagnostic assays and drug monitoring assays produced by its subsidiary, OXIS Health Products, make up the bulk of its sales. Its BXT-51072 product is currently undergoing trials, and is likely to treat inflammatory bowel disease. The company employs about 11 people and it had 2006 revenue of about $2.4 million. In February 2006, it moved key administrative functions to its U.S. FDA certified cGMP device manufacturing facility in Foster City, CA.
Oxis CEO
Steven T. GuillenNumber of Employees 5
Contact Information
468 N. Camden Dr 2nd Fl
Beverly Hills, California 90210
(310) 860-5184
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
News & Analysis
Filter by
oxis international inc. and sec - All News and Analysis
Gary Post, Managing Director and Investment Principal of Ambient Advisors, LLC, Joins OXIS' Board of Directors; Company Strengthens Short-Term Financial Position with Line of Credit from President and CEO Steve Guillen
FOSTER CITY, Calif. -- OXIS International (OTCBB:OXIS) (Nouveau Marche:OXIS) (FWB:OXI), a biopharmaceutical company focused on commercializing research assays, nutraceutical and therapeutic products related to oxidative stress and, through its majority interest in BioCheck, a leading provider of high quality immunoassay clinical kits and contract services, today announced the appointment of...
OXIS International Inks Deal with Cambridge Major Laboratories to Produce Its Potent Antioxidant Ergothioneine; Company On Schedule To Offer Nutritional Supplement By End Of Year
PORTLAND, Ore. -- OXIS International, Inc. (OTCBB:OXIS) (Nouveau Marche:OXIS) today announced that it has entered into a manufacturing agreement with Cambridge Major Laboratories (Germantown, WI) to produce Ergothioneine, which OXIS plans to make available as an over-the-counter nutraceutical supplement in 2005. The potent antioxidant will be manufactured in compliance with...
OXIS International, the Antioxidant Company, Announces That the Launch of Its New Potent Antioxidant Ergothioneine is Planned for 2005
PORTLAND, Ore. -- OXIS International, Inc. (OTCBB: OXIS) (Nouveau Marche: OXIS) today announced that availability of its potent antioxidant, Ergothioneine, is planned to occur before the end of 2005. Steven T. Guillen, President and CEO of OXIS stated, "The benefits of antioxidants are becoming more obvious to both physicians...
OXIS CEO Steve Guillen to Highlight Company's Technology Development Strategy at Rodman & Renshaw Techvest Global Healthcare Conference
PORTLAND, Ore. -- Steve Guillen, who was appointed President and Chief Executive Officer of OXIS International, Inc. (OTCBB:OXIS) (Nouveau Marche:OXIS) in February of 2005, will make his first public address outlining the company's future direction at the upcoming Techvest Global Healthcare Conference on May 4th in Paris. "Since I...
OXIS Receives $1.2 Million Loan from Axonyx to Accelerate Oxidative Stress Programs
Business Editors/Health/Medical Writers BIOWIRE2K PORTLAND, Ore.--BUSINESS WIRE--June 3, 2004 OXIS International, Inc. (OTCBB:OXIS) (Nouveau Marche:OXIS) today announced that it had secured a $1.2 million loan from its major investor, Axonyx Inc. (Nasdaq:AXYX). The loan, in the form of a one-year secured note, will be used to continue...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Steven T. Guillen | Oxis CEO |
| Michael D. Centron | CFO & Vice President |
| Sharon Ellis | COO |
| Ray Jacobs | Vice President, Marketing, sales |
| Bruce Hoffman | Director, Health |
| Randall Moeckli | Senior Director, Sales, Marketing |
| Sarah Hathaway | Manager, Regulatory Affairs |
| Anna Gralinska | |
| S. Colin Neill | Secretary |
| Richard A Davis | Director |
| Stuart S Lang | Director |
| Timothy G Biro | Director |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Joseph F Bozman Jr | Chairman of the Board |
| Gary M. Post | Board of Directors |
| John E. Repine | Board of Directors |
| Timothy C. Rodell | Board of Directors |
OXIS International will continue its innovation in the biomarker research space under the direction of CEO, Steve Guillen. Steve offers an extensive background in building highly successful commercial organizations in the diagnostic and pharmaceutical industries, including senior executive management positions at Amarin Pharmaceuticals, Elan Pharmaceuticals, Athena Diagnostics, and Athena Neurosciences. With Steve's experience, OXIS International is more committed than ever to developing new research assays designed to help researchers advance the understanding of diseases.
| Organization | Position | Status |
|---|---|---|
| Oxis International, Inc. | Oxis CEO | Current |
| Oxis Health Products, Inc. | Board of Directors | Current |
| Oxis International, Inc. | Board of Directors | Current |
| Athena Diagnostics, Inc. | Vice President, Sales and Marketing | Former |
| Athena Diagnostics, Inc. | Senior Executive | Former |
| Elan Pharmaceuticals, Inc. | Senior Executive | Former |
| Elan Corporation, PLC | Former | |
| Merck & Co. Inc. | Former | |
| University of California, Davis | B.S. In Zoology | Former |
| Organization | Position | Status |
|---|---|---|
| Oxis International, Inc. | CFO & Vice President | Current |
| Organization | Position | Status |
|---|---|---|
| Oxis International, Inc. | COO | Current |
| Organization | Position | Status |
|---|---|---|
| Oxis International, Inc. | Vice President, Marketing, sales | Current |
| Organization | Position | Status |
|---|---|---|
| Oxis International, Inc. | Director, Health | Current |
| Organization | Position | Status |
|---|---|---|
| Oxis International, Inc. | Senior Director, Sales, Marketing | Current |
| Organization | Position | Status |
|---|---|---|
| Oxis International, Inc. | Manager, Regulatory Affairs | Current |
| Organization | Position | Status |
|---|---|---|
| Lyonshare | Vice President | Current |
| Oxis International, Inc. | Current | |
| Avis Budget Group, Inc. | Director of Investor Relations | Former |
| Wesleyan University | Bachelor of Arts Degree | Former |
S. Colin Neill who becomes President of the Company, became Senior Vice President, Chief Financial Officer, Secretary and Treasurer of Pharmos in October 2006. From September 2003 to October 2006, Mr. Neill served as Chief Financial Officer, Treasurer and Secretary of Axonyx, Inc. a biopharmaceutical company that developed products and technologies to treat Alzheimer's disease and other central nervous system disorders, where he played an integral role in the merger between Axonyx and TorreyPines Therapeutics Inc., a privately-held biopharmaceutical company. From 1998 to 2001, Mr. Neill served as Senior Vice President, Chief Financial Officer, Secretary and Treasurer of ClinTrials Research Inc., a $100 million publicly traded global contract research organization in the drug development business. Mr. Neill played a key role in the successful sale of the company in 2001. Mr. Neill graduated from Trinity College, Dublin with a first class honors degree in Business / Economics and he holds a masters degree in Accounting and Finance from the London School of Economics. He is a Certified Public Accountant in New York State and a Chartered Accountant in Ireland.
| Organization | Position | Status |
|---|---|---|
| Pharmos Corporation | President, Cfo, Secretary and Treasurer | Current |
| Axonyx Inc. | CFO, Treasurer & Secretary | Current |
| Oxis Health Products, Inc. | Secretary and Director | Current |
| Oxis International, Inc. | Secretary | Current |
| Oxis Health Products, Inc. | Chairman | Current |
| Oxis International, Inc. | Board of Directors | Current |
| Oxis Health Products, Inc. | Director | Current |
| Pharmos Corporation | Treasurer | Current |
| Axonyx Inc. | Board of Directors | Current |
| BTR Incorporated | Chief Financial Officer | Former |
| Pharmos Corporation | Senior Vice President | Former |
| BTR Incorporated | Vice President Finance | Former |
| The London School of Economics | Masters Degree In Accounting and Finance | Former |
| Trinity College | Degree In Business, Economics | Former |
| Organization | Position | Status |
|---|---|---|
| Oxis International, Inc. | Chairman of the Board | Current |
| Organization | Position | Status |
|---|---|---|
| Oxis International, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Oxis International, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Oxis International, Inc. | Director | Current |
| Organization | Position | Status |
|---|---|---|
| Oxis International, Inc. | Director | Current |
| Organization | Position | Status |
|---|---|---|
| GlobeImmune Inc. | President & Chief Executive Officer | Current |
| Barofold, Inc | Founder | Current |
| Oxis Health Products, Inc. | Current | |
| Oxis International, Inc. | Board of Directors | Current |
| Oxis International, Inc. | Director | Current |
| GlobeImmune Inc. | Board of Directors | Current |
| American College of Chest Physicians | Fellow | Current |
| Rx Kinetix, Inc. | Chief Executive Officer | Former |
| Rx Kinetix, Inc. | President | Former |
| Oxis International, Inc. | President | Former |
| Oxis International, Inc. | Chief Technology Officer | Former |
| Kent International Holdings Inc | Executive Vice President of Operations and Product Development | Former |
| MTR Corporation Limited | Managing Partner | Former |
| University of North Carolina School of Medicine | M.D. | Former |
| Organization | Position | Status |
|---|---|---|
| Oxis International, Inc. | Director | Current |
Industry Transcripts by Seeking Alpha
-
Martek Biosciences Corporation F4Q09 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 16, 2009about MATK
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes

